[Comment] Can umbralisib bring PI3K δ out of the shadows?

During the past 5 years, the treatment landscape for patients with B-cell malignancies has seen a sharp increase in the array of available small molecules that target dysregulated pathways necessary for the survival and proliferation of the malignant clone.1 The phosphatidylinositol-3-kinase (PI3K) pathway has an important role in many cellular functions, including B-cell antigen receptor signalling. Selective inhibition of PI3K isoform δ-dependent signalling has direct antitumour activity and exerts pleiotropic effects in the tumour microenvironment of B-cell malignancies, inducing apoptosis and reducing proliferation.

Source: The Lancet Oncology - February 20, 2018 Category: Cancer & Oncology Authors: Jacqueline C Barrientos Tags: Comment Source Type: research